𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind comparison of levodopa, madopa, and sinemet in Parkinson disease

✍ Scribed by Dr. Shirley G. Diamond; Charles H. Markham; Leo J. Treciokas


Publisher
John Wiley and Sons
Year
1978
Tongue
English
Weight
549 KB
Volume
3
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Double-blind trial of levodopa/carbidopa
✍ Robert A. Hauser; Michel Panisset; Giovanni Abbruzzese; Linda Mancione; Nalina D 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

## Abstract We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patie

A multicenter double-blind placebo-contr
✍ Dr. C. W. Olanow; S. Fahn; M. Muenter; H. Klawans; H. Hurtig; M. Stern; I. Shoul 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 778 KB

## Abstract Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnific

Levodopa improves physical fatigue in Pa
✍ Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi

Comparison of Sinemet CR4 and standard S
✍ Dr. Joseph Jankovic; Kenneth Schwartz; Chris Vander Linden 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB

Wearing-off' effect, the most common form of levodopa-induced fluctuations, seems to be related to the short plasma half-life of the drug. More sustained plasma levodopa levels may be achieved with a new controiledrelease formulation of carbidopdevodopa, Sinemet CR4. We studied 20 patients, 12 men a